Anti-CD22 / CD22 molecule, clone MSVA-022R

Antibody in 1X PBS with 0.05% BSA, 0.05% sodium azide. CD22, also known as Siglec-2 and B-cell receptor CD22, is a B cell-restricted transmembrane glycoprotein encoded by the CD22 gene that functions as a critical regulator of B cell receptor signaling and immune tolerance. CD22 Antibody for IHC / CD22 Immunohistochemistry Antibody (clone MSVA-022R) is optimized for high-resolution detection of CD22 in formalin-fixed, paraffin-embedded tissues, enabling precise visualization of B cell populations within intact tissue architecture. CD22 expression is tightly restricted to mature B lymphocytes, including follicular and mantle zone B cells, making it a highly specific marker for identifying B cell lineage in immunohistochemistry studies.CD22 antibody, also referred to as Siglec-2 antibody or B-cell receptor CD22 antibody in the literature, is uniquely suited for tissue-based analysis where spatial context is essential. In immunohistochemistry, CD22 demonstrates a consistent membranous and cytoplasmic staining pattern that highlights B cell distribution within lymphoid organs such as lymph node, tonsil, and spleen. This staining pattern allows clear delineation of germinal centers and surrounding B cell zones, supporting detailed evaluation of lymphoid architecture in both normal and reactive tissues.The strength of CD22 Antibody for IHC is particularly evident in tissue microarray analysis, where parallel staining across a wide range of normal tissues reinforces its lineage specificity. In tissue microarray panels, CD22 staining is consistently confined to lymphoid compartments, with strong signal observed in B cell-rich regions and minimal to absent staining in epithelial, stromal, and parenchymal tissues. This high contrast between positive and negative compartments enhances interpretability and makes CD22 a reliable marker for identifying lymphoid infiltrates within complex tissue environments.In cancer tissue microarray studies, CD22 expression remains robust in B cell-derived malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and other non-Hodgkin lymphomas. Immunohistochemistry staining highlights neoplastic B cells with clear membranous and cytoplasmic localization, allowing distinction from surrounding non-neoplastic cells. Importantly, most non-B cell tumors lack CD22 expression, further supporting its use as a lineage-specific marker in diagnostic and research immunohistochemistry applications.The recombinant rabbit monoclonal format of this CD22 antibody, clone MSVA-022R, supports consistent staining intensity and low background across tissue microarray platforms, where reproducibility is critical for comparative analysis. This consistency is particularly valuable in large-scale tissue microarray studies that require uniform performance across diverse tissue types and experimental conditions.Due to its restricted expression profile, strong performance in FFPE tissues, and compatibility with tissue microarray workflows, CD22 remains an essential marker for immunohistochemistry-based investigation of B cell biology, tumor classification, and immune cell distribution. This CD22 antibody enables detailed tissue-level analysis, supporting studies of lymphoid organization, malignant B cell identification, and immune infiltration within normal and diseased tissues.This antibody is part of the broader CD22 antibody collection for studying B cell markers, immune regulation, and hematologic malignancies.This antibody is also part of a broader collection of IHC antibodies validated by tissue microarray analysis, supporting consistent staining across normal and cancer tissues.